Britain and America have established a major bilateral deal that will guarantee zero levies on UK pharmaceutical shipments entering the American market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has committed to boost expenditure on pharmaceuticals through the NHS. This commitment guarantees that import taxes on these crucial goods will be held at zero for a timeframe of the next three years.
This deal is in response to earlier threats to dramatically increase import taxes on branded pharmaceutical imports, with potential rates discussed reaching double the cost.
"This deal between the United Kingdom strengthens the global environment for cutting-edge drugs and introduces much-needed fairness to U.S.–U.K. pharmaceutical trade," a release noted.
Economic Significance
Medicines constitute one of the the United Kingdom's most significant goods shipped to the United States, which is clearly the primary market for leading UK drugmakers.
Trade data show that in the one-year period to the end of the third quarter, the UK sold medicines valued at £11.1bn to the US. This amount made up a significant portion of total UK exports in that period.
"This deal protects employment, increases capital expenditure and paves the way for the UK to emerge as a worldwide center for medical research," a minister remarked.
Specific NHS Changes
The deal entails several notable changes from the United Kingdom:
- Revised Affordability Limit: The UK will increase the affordability limit at which it judges new medicines to be unaffordable by 25%.
- Higher Drug Budget: There is a target to double total NHS spending on drugs from 0.3% of the national economy to 0.6% over the following ten-year period.
- Rebate Cap: The amount drug companies must pay back to the NHS to prevent overspending will be capped at fifteen percent. Last year, refunds were more than twenty percent.
Recent Tensions
The deal follows a ongoing dispute between the sector and the British authorities over drug pricing and approval rates.
The disagreement were heightened by claims that US consumers were charged significantly more for the equivalent treatments than patients in the Britain and the EU.
Over the last 18 months, several large drug company projects in the UK have been halted or scrapped, while substantial investments have been pledged toward projects in the United States.
One official acknowledged that the NHS needed to increase expenditure on drugs, noting that its budget allocation on drugs had decreased as a proportion of its resources over the past decade.
